Potent CXCR2 antagonist that inhibits CINC-1-mediated but not C5a-mediated Ca2+ mobilization (IC50 values are 3.4 and 6800 nM respectively). Inhibits CINC-induced chemotaxis and attenuates neutrophil accumulation in inflammatory lung injury in vivo.
Sold for research purposes under agreement from GlaxoSmithKline
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 357.16. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.8 mL||14 mL||28 mL|
|5 mM||0.56 mL||2.8 mL||5.6 mL|
|10 mM||0.28 mL||1.4 mL||2.8 mL|
|50 mM||0.06 mL||0.28 mL||0.56 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Auten et al (2001) Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. J.Pharmacol.Exp.Ther. 299 90 PMID: 11561067
Milatovic et al (2003) Impaired healing of nitrogen mustard wounds in CXCR2 null mice. Wound Repair Regen. 11 213 PMID: 12753603
If you know of a relevant reference for SB 265610, please let us know.
View Related Products by Product Action
Keywords: SB 265610, supplier, Potent, CXCR2, antagonists, Chemokine, Receptors, SB265610, GlaxoSmithKline, GSK, Chemokine, CXC, Receptors, Tocris Bioscience
3 Citations for SB 265610
Citations are publications that use Tocris products. Selected citations for SB 265610 include:
Toh et al (2011) Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol 9 e1001162 PMID: 21980263
Halpern et al (2011) Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. Cancer Lett 308 91 PMID: 21601983
Bieren et al (2015) Immune Antibodies and Helminth Products Drive CXCR2-Dependent Macrophage-Myofibroblast Crosstalk to Promote Intestinal Repair. PLoS Pathog 11 e1004778 PMID: 25806513
Do you know of a great paper that uses SB 265610 from Tocris? If so please let us know.